Last week, readers were most interested in a story about Tempus' expectations for its acquisition of cancer testing firm Ambry.

The certification is for products used in hematology instruments manufactured globally, including instruments from Abbott, Beckman Coulter, and Siemens Healthineers.

The US Food and Drug Administration granted clearances for various tests for infectious diseases, coagulation disorders, and drug susceptibility.

NEW YORK – Adaptive Biotechnologies on Thursday reported a 22 percent increase in Q3 revenues driven by an increase in minimal residual disease testing.

SensID manufactures reference materials and quality controls for molecular diagnostics with a focus on oncology and precision medicine.

The firm said on Wednesday that it has been hiring key sales and marketing personnel as it prepares to ramp up sales in 2025 of its PreTRM proteomic test.

The firm said that demand has increased for its 10-minute sepsis risk test as it can save lives, reduce hospital stays, and reduce healthcare costs.

Last week, readers were most interested in a story about the FDA's clearance of Qiagen's QiaStat-Dx Respiratory Panel Mini syndromic multiplex qPCR test.

The firm's Q3 2024 revenues rose 33 percent year over year as both its genomics and data and services revenues increased in the double-digit percent range.

The firm had received notice last year that it was out of compliance with a requirement to maintain a minimum $15 million market value of publicly held shares.

The company reported on Tuesday that its revenues jumped 8 percent in North America and Europe during the third quarter but fell slightly in the rest of the world.

The whole-exome sequencing and whole-transcriptome sequencing-based test is approved for molecular profiling of solid tumors.